Characterising the safety profile of lurasidone in clinical practice: A drug utilisatio and safety study using a United Kingdom primary care database

07/04/2017
15/03/2024
EU PAS number:
EUPAS18536
Study
Planned
Subscribe
Download as PDF
Study identification

EU PAS number

EUPAS18536

Study ID

18537

Official title and acronym

Characterising the safety profile of lurasidone in clinical practice: A drug utilisatio and safety study using a United Kingdom primary care database

DARWIN EU® study

No

Study countries

United Kingdom

Study description

The study will describe drug utilization patters and characterize the safety profile of lurasidone compared to other second generation antipsychotics in a real world UK primary healthcare setting

Study status

Planned
Research institutions and networks

Institutions

OXON Epidemiology
Spain
United Kingdom
First published:
15/03/2024
Institution Laboratory/Research/Testing facility Non-Pharmaceutical company ENCePP partner

Contact details

Nawab Qizilbash MBChB MRCP(UK) BSc MSc DPhil(Oxon.)

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Sunovion Pharmaceuticals Europe Ltd
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)